---
schema_version: "secwatch.filing_event.v1"
accession: "0001551152-23-000026"
form_type: "8-K"
ticker: "ABBV"
cik: "0001551152"
company_name: "AbbVie Inc."
filed_at: "2023-07-06T23:59:59+00:00"
generated_at: "2026-06-13T11:46:28.698631+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# AbbVie lowers 2023 adjusted EPS guidance to $10.57-$10.97 on $280M Q2 IPR&D charge

## Summary
- Q2 2023 includes $280M pre-tax acquired IPR&D and milestones expense, reducing EPS by $0.15.
- Full-year 2023 adjusted diluted EPS guidance reduced to $10.57-$10.97 from $10.72-$11.12.
- Q2 2023 adjusted diluted EPS guidance now $2.75-$2.85, down from $2.90-$3.00 prior.
- Company does not forecast further IPR&D expense beyond Q2 due to uncertainty of timing.
- Charge stems from collaborations, licensing agreements, and other asset acquisitions.

## SEC filing metadata
- accession: 0001551152-23-000026
- form_type: 8-K
- ticker: ABBV
- cik: 0001551152
- company_name: AbbVie Inc.
- filed_at: 2023-07-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1551152/000155115223000026/0001551152-23-000026-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1551152/000155115223000026/abbv-20230706.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001551152-23-000026
- JSON: https://secwatch.observer/filing/0001551152-23-000026.json
- Plain text: https://secwatch.observer/filing/0001551152-23-000026.txt

## Key facts
- Earnings Releases
  AbbVie Inc. updated its second quarter of 2023 guidance (reaffirmed).
  - Period: second quarter of 2023
  - Guidance: reaffirmed
  - Result: guidance update
  source text: Reported GAAP earnings and adjusted non-GAAP earnings for the second quarter of 2023 are expected to include acquired IPR&D and milestones expense of $280 million on a pre-tax basis, representing an unfavorable impact of $0.15 to both GAAP diluted earnings per share and adjusted non-GAAP diluted earnings per share. Results for the quarter ended June 30, 2023 have not been finalized and are subject to our financial statement closing procedures.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1551152/000155115223000026/0001551152-23-000026-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.